BUZZ-<a href="https://laohu8.com/S/ANRO">Alto Neuroscience</a> rises after plans to accelerate depression drug development** Shares of drug developer Alto Neuroscience ANRO.N rise 8.2% to $6.58 premarket
** Company says it plans to accelerate the development of its experimental drug, ALTO-207, for people with treatment resistant depression
** Treatment-resistant depression is a type of major depressive disorder where symptoms do not improve after trying at least two different antidepressant medications at adequate doses and for sufficient time
** The $50 million private placement announced earlier today supports expanded development of ALTO-207 - ANRO
** Company expects to begin late-stage study by early 2027
** As of last close, stock up 43.7% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.